Eli Lilly's Omvoh shows long-term remission and improved quality of life for ulcerative colitis patients in new trial results ...

Eli Lilly’s Omvoh (mirikizumab-mrkz) has shown continued benefit after four years in a Phase III open-label extension trial ...

Eli Lilly has halted a study of an experimental drug, designed to prevent obesity patients from losing too much muscle, due ...

Eli Lilly continues to establish its dominance in the growing market for GLP-1 therapies. The company's oral candidate for ...

Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.

If you have been keeping an eye on Eli Lilly’s stock, you are not alone, and you are probably wondering if now is the right ...

Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced breast ...

Eli Lilly’s valuation has compressed significantly from last year’s highs, despite improving fundamentals. See why I rate LLY ...

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients ...

US pharma major Eli Lilly has halted a study of an experimental drug, bimagrumab, designed to prevent obesity patients from ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug ...

Novo Nordisk's and Eli Lilly's blockbuster weight-loss drugs should be the first medicines doctors reach for to treat obesity ...